Skoči na glavni sadržaj

Izvorni znanstveni članak

POSTTRANSPLANTATION ANEMIA 6 MONTHS AFTER KIDNEY TRANSPLANTATION

JELENA BANJEGLAV ; Medicinski fakultet Sveučilišta J. J. Strossmayera u Osijeku, Osijek, Hrvatska
LADA ZIBAR ; Medicinski fakultet Sveučilišta J. J. Strossmayera u Osijeku, Osijek, Hrvatska


Puni tekst: hrvatski pdf 2.105 Kb

str. 4-11

preuzimanja: 944

citiraj


Sažetak

Aim: to determine the prevalence of anemia and risk factors that can affect on it six months after kidney transplantation (tX) at the university Hospital osijek (kbco) in period from 2007 to march 2012. methods: the study included 55 patients, mean age 49 ± 11 (27 - 0) years, after deceased donor kidney tX in kbco from 2007 to march 2012. two grafts did not survive a week (one for sudden death and another for the renal artery thrombosis, in the first 24 hours, respectively). the method of the survey comprised of taking data from the medical records and statistical analysis (sPss). Results: Posttransplantation anemia (Pta) and is defined by serum hemoglobin (Hb) concentration less than 110 g/l at 3 months after tX. the prevalence of Pta was 28.85%. Pta was more frequent among women (P=0,025). Patients with Pta were significantly longer hospitalized (P=0.002). Pta was more frequent in patients with sepsis after tX (P=0,03), in those with dehiscent postoperative wound (P=0,021) and in the patients with acute kidney transplant rejection (P=0.004). although delayed graft function was not found significantly related to the Pta, decreased kidney function indicating feature, i.e. number of hemodialysis (Hd) needed after tX (P=0.004) and after Hd duration (P=0,008), were associated with the Pta significantly. furthermore, serum creatinine concentration, at the time of hospital release, were significantly higher in those with Pta (P=0.035). there is statistically significant correlation between mean Hb and cratininemia at 3 months after tX. immunosuppressive drugs and other studied medication, frequently used by kidney transplanted patients, were not related to the Pta. the anemia required erythropoietin substitution in 20 of 53 patients, while 20 patients received blood transfusions.
Conclusion: Pta presents a great problem among the kidney transplanted patients with prevalence in our patients similar to that in previously published reports. this study had confirmed some of the well known risk factors for anemia in kidney transplant patients, like gender and graft function, but also there had been noticed few risk factors that can be prevented, like dehiscent postoperative wound and sepsis. Pta often requires erythropoietin substitution and blood transfusions, increasing the expenses of kidney transplantation and posttransplantation treatment. therefore, prevention of Pta is, both medically and economically, justifide.

Ključne riječi

posttransplantation anemia; kidney transplantation

Hrčak ID:

99530

URI

https://hrcak.srce.hr/99530

Datum izdavanja:

3.4.2013.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.631 *